- Introduced at a ‘High WAC’ with a 5% lower price than the original, strengthening 바카라사이트 목록 competitiveness covering all indications
- Signs supply agreement with major U.S. hospital group, anticipates strong sales with product supply from 바카라사이트 목록 day
- Targeting U.S. ‘open 바카라사이트 목록’ representing 30% of the denosumab 바카라사이트 목록, following successful ‘Vegzelma’ model
[by Kang, In Hyo] Celltrion announced on July 8 that it launched its bone disease treatment, ‘Stoboclo·Osenvelt (denosumab),’ in the United States earlier this month, officially entering the global denosumab market, which is valued at around KRW 9 trillion (approximately USD 6.5 billion).
The newly launched product is a biosimilar (biopharmaceutical generic drug) of Prolia·XGEVA, for which 바카라사이트 목록 received full-label approval, covering all indications, from the U.S. Food and Drug Administration (FDA) in early March of this year, in line with the original drug. In addition, 바카라사이트 목록 finalized a patent agreement with the original drug developer, thereby securing a foundation for stable market entry in the United States.
Stoboclo·Osenvelt was launched in the U.S. at a high wholesale acquisition cost (High WAC), set approximately 5% below that of the original product. As with previously introduced autoimmune disease treatments, ‘Zymfentra’ (infliximab, marketed as Remsima SC in the U.S.), ‘Yuflyma’ (adalimumab), and ‘Steqeyma’ (ustekinumab), the product will be distributed through direct sales by 바카라사이트 목록’s U.S. subsidiary.
Coinciding with the launch of Stoboclo and Osenvelt, 바카라사이트 목록 succeeded in securing an early foothold in the U.S. market by signing a supply agreement with a major hospital group of substantial scale. With product supply to these hospitals beginning immediately upon launch, the company anticipates a rapid increase in actual prescriptions and a swift expansion of market performance.
바카라사이트 목록 plans to concentrate its efforts on the U.S. denosumab ‘open market,’ which accounts for about 30% of the total market. The open market consists of medical institutions directly supported by the U.S. government, and it is characterized by minimal influence from insurance companies or pharmacy benefit managers (PBMs). Hence, the sales capabilities and product competitiveness of pharmaceutical companies are critical to success in market conquest. 바카라사이트 목록 has already demonstrated strong performance in the open market by directly launching its anticancer biosimilar ‘Vegzelma’ (bevacizumab), increasing its market share to 6% by the end of 2024.
바카라사이트 목록 also aims to successfully establish a strong presence in the public and private insurance market by smoothly advancing negotiations with the three major PBMs, in addition to its focus on the open market. In particular, recognizing that the majority of osteoporosis patients are in the postmenopausal age group, the company plans to accelerate efforts to secure formulary placement in the ‘Medicare’ system, where demand for bone disease treatments is especially high. Given 바카라사이트 목록’s ongoing negotiations with major PBMs and ‘public insurance’ programs through its existing product portfolio, Stoboclo and Osenvelt are likewise expected to achieve rapid listing results.
바카라사이트 목록 also intends to speed up its marketing efforts targeting healthcare professionals. Building on its established communication with key medical experts in related fields such as rheumatology and oncology, developed through the promotion of its autoimmune disease treatments, the company plans to actively utilize this network to drive prescription growth as it enters the bone disease treatment market.
With the expansion of its product portfolio, 바카라사이트 목록 is also expected to see further growth in future sales. As of last year, the combined global sales of Prolia and XGEVA, the original products of Stoboclo and Osenvelt, reached around USD 6.599 billion (approximately KRW 9.2 trillion). Of this total, approximately USD 4.392 billion was recorded in the U.S. market alone, accounting for 67% of total sales.
“The launch of Stoboclo and Osenvelt will offer U.S. healthcare professionals and patients a broader range of treatment options for bone diseases, thereby enhancing access to healthcare,” said Thomas Nusbickel, Chief Commercial Officer of 바카라사이트 목록 USA. “Leveraging 바카라사이트 목록’s proven sales force and distribution network built through existing products, we will work to expand prescriptions in the open market while smoothly advancing negotiations with PBMs to quickly gain a competitive foothold in the bone disease treatment market,” he added.